Activity Summary:
Patients with interferon gamma (IFN-γ)-driven diseases such as hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS) face significant diagnostic and therapeutic challenges, with delays in diagnosis and limited effective treatments often resulting in poor outcomes. Despite advances in understanding the role of IFN-γ in these conditions, there remains an unmet need for more precise diagnostic tools and faster, targeted therapies to manage the hyperinflammatory states that characterize these diseases.

Activity Summary:
Patients with interferon gamma (IFN-γ)-driven diseases such as hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS) face significant diagnostic and therapeutic challenges, with delays in diagnosis and limited effective treatments often resulting in poor outcomes. Despite advances in understanding the role of IFN-γ in these conditions, there remains an unmet need for more precise diagnostic tools and faster, targeted therapies to manage the hyperinflammatory states that characterize these diseases.

Activity Summary:
Patients with plexiform neurofibromas (PN) associated with neurofibromatosis type 1 (NF1) experience considerable morbidity, a poor quality of life, and increased mortality. Research efforts have led to earlier diagnosis, new monitoring approaches, emerging treatment options, and considerations for surgical intervention. To this end, it is critical that pediatric oncologists as well as other members of the multidisciplinary team neurologists caring for patients with NF1-PN are up to date on recent advances. In this podcast lecture library, Dr. Armstrong uses a case-based discussion to address the heterogeneity and complexity of this condition as well as considerations for the use of emerging therapies when making individualized management decisions among diverse patients.

Activity Summary:
Patients with plexiform neurofibromas (PN) associated with neurofibromatosis type 1 (NF1) experience considerable morbidity, a poor quality of life, and increased mortality. Research efforts have led to earlier diagnosis, new monitoring approaches, emerging treatment options, and considerations for surgical intervention. 

In this video presentation, Dr Armstrong uses a case-based discussion to address the heterogeneity and complexity of this condition as well as considerations for the use of emerging therapies when making individualized management decisions among diverse patients.

Activity Summary:
Bispecific antibodies represent a much-needed option for diverse patients with relapsed/refractory multiple myeloma (RRMM). This podcast activity will highlight key clinical trial evidence leading to approval of bispecific antibodies and will provide guidance on safely incorporating these agents into RRMM treatment paradigms. Clinical case scenarios will also be discussed to optimize and sequence bispecific antibodies to enable improved outcomes among distinct patient subsets.

Activity Summary:
In this podcast series, Dr. Orlowski, Dr. Raje, and Dr. Voorhees inform and guide participants on latest developments from clinical trials on quadruplet and triplet regimens, based on updates from the European Hematology Association (EHA) 2024 meeting. Using clinical case scenarios, they’ll clarify clinical endpoints and outcomes to enable safe and effective frontline regimen choices among diverse patients with newly diagnosed multiple myeloma (NDMM) who have distinct needs. Listen to the available episodes as experts lay the foundation for optimal first-line, maintenance, transplantation, and subsequent therapy choice based on the risk profile of patients, to ultimately improve outcomes in multiple myeloma (MM).

Activity Summary:
In these mini-modules, expert faculty inform and guide participants on latest developments from clinical trials on quadruplet and triplet regimens, based on updates from the European Hematology Association (EHA) 2024 meeting. By using clinical case scenarios, this activity clarifies clinical endpoints and outcomes to enable safe and effective frontline regimen choices among diverse patients with newly diagnosed multiple myeloma (NDMM) who have distinct needs. Dr. Orlowski, Dr. Raje, and Dr. Voorhees lay the foundation for optimal first-line, maintenance, transplantation, and subsequent therapy choice based on the risk profile of patients, to ultimately improve outcomes in multiple myeloma (MM).

Activity Summary:
Clinical Viewpoints MF includes a curriculum that highlights the very latest clinical data in myelofibrosis. Slides are developed and updated throughout the year by leading MF expert physicians. All content is reviewed and approved by the Clinical Viewpoints MF Planning Committee.

Myelofibrosis is a myeloproliferative neoplasm characterized by clonal proliferation of myeloid cells, bone marrow fibrosis and cytopenias, extramedullary hematopoiesis and hepatosplenomegaly, increased pro-inflammatory cytokine production, and systemic symptoms. Patients with MF also have a propensity toward leukemic transformation. Allogeneic hematopoietic stem cell transplantation (aHCT) is the only curative therapy for patients with MF; however, transplant-related morbidity and mortality precludes this option for the majority of patients. In the last decade, four targeted therapies have been approved for the treatment of MF, all JAK2 inhibitors, ruxolitinib, fedratinib, pacritinib, and momelotinib. Moreover, there are a number of novel therapeutic targets with drug candidates in late-stage (phase II or III) clinical development for the treatment of MF. This case-based slide kit discusses the pathophysiology, burden diagnosis, current and future treatment strategies, risk stratification, adverse events associated with therapies as well as the importance of patient-centered care.

Updated information is noted on the slide in the upper right hand corner. Please note that participants who have previously claimed credit for this activity should not claim duplicate credit based on the updates.

Activity Summary:
Myelofibrosis is a myeloproliferative neoplasm characterized by clonal proliferation of myeloid cells, bone marrow fibrosis and cytopenia, extramedullary hematopoiesis and hepatosplenomegaly, increased pro-inflammatory cytokine production, and systemic symptoms. In the last decade, four targeted therapies have been approved for the treatment of MF, all JAK2 inhibitors, ruxolitinib, fedratinib, pacritinib, and momelotinib. Moreover, there are a number of novel therapeutics in late-stage clinical development for the treatment of MF. This podcast will provide expert interpretation of new and emerging data on the pathophysiology, diagnosis and treatment of MF presented at the 2024 European Hematology Association (EHA2024) Hybrid Congress, June 13-16, Madrid, Spain.

Activity Summary:
These are exciting times in the therapeutic landscape of multiple myeloma (MM) due to introduction of quadruplet regimens, novel therapies, and rapid updates to existing treatment paradigms. It is crucial that healthcare professionals are well-aware of new evidence and have the knowhow to incorporate updates into their respective practices. This activity is designed to aid busy clinicians in staying abreast of recent insights into safely integrating monoclonal antibody-based quadruplet and triplet regimens in the first-line treatment of diverse patients with newly diagnosed MM (NDMM).

This podcast will ensure that HCPs who treat / manage patients with NDMM are up-to-date on key data presented at the 2024 European Hematology Association Annual Congress (EHA 2024), June 13-16, 2024 in Madrid, Spain and will aid learners in safely applying recent evidence into practice.

Activity Summary:
Immune thrombocytopenic purpura (ITP) is an acquired autoimmune disease characterized by a low platelet count, purpura, and hemorrhagic episodes caused by antiplatelet autoantibodies. Diagnosis is typically made by excluding the known causes of thrombocytopenia. Recent advancements in pediatric ITP treatment show promise for personalized medicine and better outcomes. Healthcare providers can improve treatment decisions and patient quality of life by staying updated on these developments. This podcast will provide expert interpretation of new and emerging data on the pathophysiology, diagnosis and treatment of pediatric ITP presented at the European Hematology Association (EHA) 2024 Hybrid Congress, June 13-16, Madrid, Spain.

Activity Summary:
Myelofibrosis is a myeloproliferative neoplasm characterized by clonal proliferation of myeloid cells, bone marrow fibrosis and cytopenia, extramedullary hematopoiesis and hepatosplenomegaly, increased pro-inflammatory cytokine production, and systemic symptoms. In the last decade, four targeted therapies have been approved for the treatment of MF, all JAK2 inhibitors, ruxolitinib, fedratinib, pacritinib, and momelotinib. Moreover, there are a number of novel therapeutics in late-stage clinical development for the treatment of MF. This clinical clip will provide expert interpretation of new and emerging data on the pathophysiology, diagnosis and treatment of MF presented at the 2024 European Hematology Association (EHA2024) Hybrid Congress, June 13-16, Madrid, Spain.

Activity Summary:
These are exciting times in the therapeutic landscape of multiple myeloma (MM) due to introduction of quadruplet regimens, novel therapies, and rapid updates to existing treatment paradigms. It is crucial that healthcare professionals are well-aware of new evidence and have the knowhow to incorporate updates into their respective practices. This activity is designed to aid busy clinicians in staying abreast of recent insights into safely integrating monoclonal antibody-based quadruplet and triplet regimens in the first-line treatment of diverse patients with newly diagnosed MM (NDMM).

This clinical clip will ensure that HCPs who treat / manage patients with NDMM are up-to-date on key data presented at the 2024 European Hematology Association Annual Congress (EHA 2024), June 13-16, 2024 in Madrid, Spain and will aid learners in safely applying recent evidence into practice.

Activity Summary:
Immune thrombocytopenic purpura (ITP) is an acquired autoimmune disease characterized by a low platelet count, purpura, and hemorrhagic episodes caused by antiplatelet autoantibodies. Diagnosis is typically made by excluding the known causes of thrombocytopenia. Recent advancements in pediatric ITP treatment show promise for personalized medicine and better outcomes. Healthcare providers can improve treatment decisions and patient quality of life by staying updated on these developments. This clinical clip will provide expert interpretation of new and emerging data on the pathophysiology, diagnosis and treatment of pediatric ITP presented at the European Hematology Association (EHA) 2024 Hybrid Congress, June 13-16, Madrid, Spain.

Activity Summary:
These clinical clips and podcasts are accredited, on-demand presentations that feature experts discussing recent clinical updates, hot topics and treatment options that were presented at EHA June 13-16, 2024. These activities are designed to keep healthcare professionals abreast of the most recent clinical findings.

This series of conference highlights will cover newly diagnosed multiple myeloma, pediatric idiopathic thrombocytopenia purpura (ITP), and myelofibrosis. Please click the links to participate in each of these activities. At the conclusion of the video and/or podcast, please return to that page to complete your evaluation and receive CME/CE credit.

Activity Summary:
Precision therapy has revolutionized the treatment of lung cancer and has made personalized treatment a reality. To this end, the therapeutic landscape for patients with metastatic non-small cell lung cancer (NSCLC) harboring EGFR mutations has been evolving rapidly. Indeed, ongoing studies are investigating novel agents and combinations that will play a role in earlier and subsequent treatment settings of EGFR mutated NSCLC and are also exploring the utility of additional biomarkers in guiding therapy in EGFR mutated advanced NSCLC. Considering a continual influx of such progress from ongoing trials, clinicians and healthcare professionals will need guidance from key opinion leaders in sifting through recent evidence and identifying practice-changing updates.

This podcast ensures clinicians are up-to-date on key data for NSCLC harboring EGFR mutations presented at the 2024 ASCO Annual Meeting in Chicago, IL May 31 – June 4, 2024 and aids learners in safely applying recent evidence into practice.

Activity Summary:
Precision therapy has revolutionized the treatment of lung cancer and has made personalized treatment a reality. To this end, the therapeutic landscape for patients with metastatic non-small cell lung cancer (NSCLC) harboring EGFR mutations has been evolving rapidly. Indeed, ongoing studies are investigating novel agents and combinations that will play a role in earlier and subsequent treatment settings of EGFR mutated NSCLC and are also exploring the utility of additional biomarkers in guiding therapy in EGFR mutated advanced NSCLC. Considering a continual influx of such progress from ongoing trials, clinicians and healthcare professionals will need guidance from key opinion leaders in sifting through recent evidence and identifying practice-changing updates.

This clinical clip ensures clinicians are up-to-date on key data for NSCLC harboring EGFR mutations presented at the 2024 ASCO Annual Meeting in Chicago, IL May 31 – June 4, 2024 and aids learners in safely applying recent evidence into practice.

Activity Summary:
In this podcast series, Drs. Andrew Armstrong and Tanya Dorff will clarify the rationale and best-practice approaches for HRRm testing to guide therapeutic strategies in metastatic prostate cancer. Clinical case scenarios are used to enhance the learning experience and provide practical considerations to achieve improved outcomes among patients.

Activity Summary:
The most recent guidelines recommend germline and/or somatic homologous recombination repair (HRR) gene panel testing to identify patients with metastatic prostate cancer that can benefit from poly-ADP ribose polymerase (PARP) inhibitors. However, HRR gene mutation (HRRm) testing rates are low and as a result, many patients with metastatic prostate cancer are unable to avail of these new therapies that have the potential to improve survival outcomes. This has been attributed to limited awareness about testing, inadequate sample, challenges with reimbursement, lack of patient counseling, and costs. Improving clinician and allied healthcare professional familiarity with HRRm testing guidelines and implementation recommendations, is therefore of utmost importance.

In these Mini Modules, Drs. Andrew Armstrong and Tanya Dorff use a discussion and case-based format to clarify the rationale for HRRm testing in metastatic prostate cancer and ensure better integration of the latest guidelines for testing by addressing barriers. The overall aim is to enable appropriate utilization of HRRm testing to ultimately improve outcomes among patients.

Activity Summary:
Patients with relapsed/refractory multiple myeloma (RRMM) are associated with poor survival outcomes and are in continual need of more effective therapies. Currently, a multitude of agents including monoclonal antibodies, proteosome inhibitors, immunomodulatory agents, bispecific antibodies, chimeric antigen receptor (CAR) T-cell therapy, and selinexor are available for patients with RRMM. More recently, the bispecific antibodies, teclistamab, elranatamab, and talquetamab have been approved for the treatment of RRMM and are also under investigation in combination with other agents and in different settings of MM.

In this podcast series, leading experts summarize the rationale/mechanism of action and clinical evidence on approved and emerging bispecific antibody therapy in RRMM and aid participants in using these agents safely by using clinical vignettes. The activity also provides guidance on early recognition of key adverse events and strategies to manage them, to ultimately improve outcomes for patients with RRMM.

Activity Summary:
Patients with relapsed/refractory multiple myeloma (RRMM) are associated with poor survival outcomes and are in continual need of more effective therapies. Currently, a multitude of agents including monoclonal antibodies, proteosome inhibitors, immunomodulatory agents, bispecific antibodies, chimeric antigen receptor (CAR) T-cell therapy, and selinexor are available for patients with RRMM. More recently, the bispecific antibodies, teclistamab, elranatamab, and talquetamab have been approved for the treatment of RRMM and are also under investigation in combination with other agents and in different settings of MM.

In this roundtable discussion, leading experts summarize the rationale/mechanism of action and clinical evidence on approved and emerging bispecific antibody therapy in RRMM and aid participants in using these agents safely by using clinical vignettes. The activity also provides guidance on early recognition of key adverse events and strategies to manage them, to ultimately improve outcomes for patients with RRMM.

Activity Summary:
Conversations in Hematology/Oncology: Incorporating Key Updates in the Treatment of Follicular Lymphoma: A Discussion Following ASH 2023 on Assimilating Practice-Changing Breakthroughs is a podcast discussion between key opinion leaders to identify and integrate crucial advances in follicular lymphoma presented at the 2023 American Society of Hematology (ASH) annual conference.

Activity Summary:
Myelofibrosis (MF) is a complex myeloproliferative neoplasm (MPN) that profoundly impacts the lives of patients. Recent years have witnessed advancements in risk stratification, symptom management, and treatment options for patients with MF. Unmet needs include alleviation of limiting thrombocytopenia and anemia, halting disease progression to acute leukemia, and extending survival. This has stimulated the development and investigation of a number of new agents for MF treatment. This Conversations in MF podcast will discuss the most clinically relevant data and emerging strategies into practice to improve outcomes for patients with MF presented from the 2023 international meetings of the American Society of Clinical Oncology (ASCO), European Hematology Association (EHA) and Society of Hematologic Oncology (SOHO).

Activity Summary:
Conversations in Hematology/Oncology: Incorporating Key Updates in the Treatment of Follicular Lymphoma: A Discussion Following ASH 2023 on Assimilating Practice-Changing Breakthroughs is a discussion between key opinion leaders to identify and integrate crucial advances in follicular lymphoma presented at the 2023 American Society of Hematology (ASH) annual conference.